No Data
No Data
Selling Arrowhead Pharmaceuticals Shares at a Lower Price Than Current Market Value May Have Been a Costly Mistake for Insiders
Hospital Stocks Are Ready to Rebound, Deutsche Bank Says
Proposed Medicaid Cuts Would Devastate Local Economies: Report -- Barrons.com
Express News | Arrowhead Pharmaceuticals : Leerink Partners Cuts Target Price to $22 From $24
Arrowhead Pharmaceuticals Insider Sold Shares Worth $774,975, According to a Recent SEC Filing
Morgan Stanley Maintains Arrowhead Pharmaceuticals(ARWR.US) With Hold Rating, Maintains Target Price $29